Skip to main content
INKON Life Technology Co., Ltd. logo

INKON Life Technology Co., Ltd. — Investor Relations & Filings

Ticker · 300143 ISIN · CNE100000XF6 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,851 across all filing types
Latest filing 2021-05-24 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300143

About INKON Life Technology Co., Ltd.

https://www.inkonlife.com

INKON Life Technology Co., Ltd. specializes in the development and manufacture of advanced medical equipment and digital healthcare solutions. The company focuses on two primary sectors: radiotherapy equipment and digital medical services. Its core product portfolio includes high-precision radiotherapy systems, such as the Gamma Knife, and medical infusion systems. INKON Life leverages Internet of Things (IoT) technology to provide integrated digital hospital solutions, aiming to improve clinical efficiency and patient outcomes. The company serves oncology centers and medical institutions by providing comprehensive cancer treatment solutions and smart healthcare management platforms. By combining medical engineering with digital innovation, INKON Life focuses on the modernization of radiotherapy and the digital transformation of healthcare delivery.

Recent filings

Filing Released Lang Actions
备考审阅报告
Audit Report / Information Classification · 95% confidence The document is a detailed "备考审阅报告" (pro forma review report) for 盈康生命科技股份有限公司, including pro forma consolidated financial statements such as balance sheets, income statements, and extensive notes. It references the audit firm 信永中和会计师事务所 and includes detailed financial data for 2019 and 2020 fiscal years. The document discusses the basis and methods of preparation, including same-control business combinations and major asset restructuring. It is not a brief announcement or a certification letter but contains substantive financial data and analysis. The document is not a full annual report (10-K) but a standalone audit/review report on pro forma financials prepared for a major asset restructuring purpose. Therefore, it fits best under Audit Report / Information (AR). FY 2020
2021-05-24 Chinese
董事会关于本次重大资产重组摊薄即期回报情况及相关填补措施和相关主体承诺的说明
Capital/Financing Update Classification · 95% confidence The document is a detailed explanation from the board of directors regarding a major asset restructuring transaction, specifically addressing the dilution of immediate returns and related compensation measures. It references regulatory guidelines from the China Securities Regulatory Commission and includes commitments from directors, senior management, and controlling shareholders about the transaction and its impact on earnings per share. The content focuses on the transaction details, earnings impact, risk disclosures, and governance measures related to the restructuring. This type of document is typical of a Capital/Financing Update (CAP) as it provides updates on a significant financing or capital transaction and related measures. The document length is under 5,000 characters but contains substantive content about the transaction and related commitments, not merely an announcement of a report publication. Therefore, it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). It is not an Annual Report, Interim Report, or Earnings Release as it does not contain comprehensive financial statements or earnings highlights but rather focuses on the restructuring transaction and its impact. Hence, the most appropriate classification is Capital/Financing Update (CAP).
2021-05-24 Chinese
董事会关于本次重组相关主体不存在依据《关于加强与上市公司重大资产重组相关股票异常交易监管的暂行规定》第十三条不得参与任何上市公司重大资产重组情形的说明
Regulatory Filings Classification · 95% confidence The document is a statement from the board of directors of 盈康生命科技股份有限公司 regarding the compliance of the parties involved in a major asset restructuring transaction with regulatory provisions. It specifically addresses that none of the parties are prohibited from participating in the restructuring under the relevant regulatory rules. The document does not contain financial statements, detailed financial data, or a full report on the transaction. Instead, it is a regulatory compliance statement related to a major asset restructuring. This fits best under the category of Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other specific categories.
2021-05-24 Chinese
董事会关于本次重大资产重组符合《关于规范上市公司重大资产重组若干问题的规定》第四条规定的说明
Regulatory Filings Classification · 95% confidence The document is a statement from the board of directors of 盈康生命科技股份有限公司 regarding a major asset restructuring transaction. It explains compliance with regulatory provisions related to significant asset reorganizations, specifically referencing the relevant regulatory guidelines. The content focuses on the board's explanation and confirmation that the transaction meets regulatory requirements. There are no financial statements, detailed financial data, or comprehensive report content. The document is relatively short (881 characters) and serves as an official announcement or explanation rather than a full report. Therefore, it fits best as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2021-05-24 Chinese
董事会关于评估机构的独立性、评估假设前提的合理性、评估方法与评估目的的相关性以及评估定价的公允性的说明
Regulatory Filings Classification · 95% confidence The document is a statement from the board of directors of 盈康生命科技股份有限公司 regarding the independence of the asset evaluation agency, the reasonableness of evaluation assumptions, the relevance of evaluation methods to the evaluation purpose, and the fairness of the evaluation pricing. It discusses an asset acquisition transaction and the related asset appraisal report. The document does not contain actual financial statements or detailed financial data but rather an explanation and confirmation of the evaluation process and fairness of pricing related to a major asset restructuring transaction. This fits the category of a Regulatory Filing (RNS) as it is a regulatory disclosure about the evaluation process and fairness related to a transaction, not the transaction announcement itself or a full financial report.
2021-05-24 Chinese
第五届监事会第八次（临时）会议决议公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of resolutions passed by the Supervisory Board (监事会) of 盈康生命科技股份有限公司 regarding a major asset restructuring involving the purchase of 100% equity of 苏州广慈肿瘤医院有限公司. It includes detailed descriptions of the transaction terms, pricing, payment arrangements, performance commitments, legal compliance, and related approvals. The document repeatedly states that these resolutions need to be submitted to the shareholders' meeting for approval. The content is focused on the supervisory board's review and approval of a major asset acquisition and related agreements, which is typical for a regulatory announcement related to a major asset restructuring. It is not a full annual or interim report, audit report, or earnings release. It is not a proxy statement or voting results announcement. It is not a merger proxy or tender offer filing but relates to a major asset acquisition. The document is a formal regulatory announcement of the Supervisory Board's resolutions on a major asset restructuring and related matters, consistent with a Regulatory Filing (RNS) category. The document length is over 12,000 characters, so it is not a mere report publication announcement. Therefore, the best classification is Regulatory Filings (RNS).
2021-05-24 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.